2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumor action

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8492570
APP PUB NO 20090221841A1
SERIAL NO

12235392

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to the use of 2-substituted estra-1,3,5(10)-triene-3-yl sulfamates of general formula I, in addition to their pharmaceutically acceptable salts for producing a medicament. Said compounds have an anti-tumour action.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
STERIX LIMITED190 BATH ROAD SLOUGH BERKSHIRE SL1 3XE

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bothe, Ulrich Berlin, DE 38 212
Gege, Christian Ehingen/Donau, DE 69 411
Hillisch, Alexander Jena, DE 72 444
Kosemund, Dirk Erfurt, DE 75 269
Peters, Olaf Jena, DE 38 156
Regenhardt, Wilko Osterode, DE 6 19
Siemeister, Gerhard Berlin, DE 144 993
Unger, Eberhard Cospeda, DE 10 56

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 23, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00